Medical use for tachykinin antagonists

Details Medical use for tachykinin antagonists Medical use for tachykinin antagonists

2008-03-11

2008-03-11

Wang, Shengjun (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S397000, C514S299000, C514S619000

Reexamination Certificate

active

07342028

ABSTRACT:
The present invention relates to the use of tachykinin antagonists, including substance P antagonists and other neurokinin antagonists, in the treatment of emesis. Also described are novel tachykinin antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use.whereinR represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide;R1is selected from halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups;R2and R3, which may be the same or different, each independently are selected from hydrogen and halogen atoms and C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groups;n represents zero, 1 or 2;and pharmaceutically acceptable salts and solvates thereof.

REFERENCES:
patent: 4031226 (1977-06-01), Soudijn et al.
patent: 4066772 (1978-01-01), Vandenberk et al.
patent: 4695578 (1987-09-01), Coates et al.
patent: 4753789 (1988-06-01), Tyers et al.
patent: 4839465 (1989-06-01), Singh et al.
patent: 4886808 (1989-12-01), King
patent: 4906755 (1990-03-01), Gittos
patent: 4910193 (1990-03-01), Buchheit
patent: 4920227 (1990-04-01), Pelletier et al.
patent: 5102667 (1992-04-01), Dubroeucq et al.
patent: 5202333 (1993-04-01), Berger et al.
patent: 5321032 (1994-06-01), Matsuo et al.
patent: 5360800 (1994-11-01), Coates et al.
patent: 5360820 (1994-11-01), Hagan et al.
patent: 5538982 (1996-07-01), Hagan et al.
patent: 5547964 (1996-08-01), Hagan et al.
patent: 5576317 (1996-11-01), Gonsalves
patent: 5719147 (1998-02-01), Dorn et al.
patent: 5798363 (1998-08-01), Hagan et al.
patent: 6048859 (2000-04-01), Dorn et al.
patent: 6096742 (2000-08-01), Crocker et al.
patent: 6235735 (2001-05-01), Dorn et al.
patent: 6326383 (2001-12-01), Hagan et al.
patent: 11230/88 (1988-08-01), None
patent: 14134/88 (1988-10-01), None
patent: 0 247 266 (1987-12-01), None
patent: 0 284 942 (1988-10-01), None
patent: 0 327 099 (1989-08-01), None
patent: 0 394 989 (1990-10-01), None
patent: 0 436 334 (1991-07-01), None
patent: 0 446 706 (1991-09-01), None
patent: 0 482 539 (1992-04-01), None
patent: 0 484 719 (1992-05-01), None
patent: 499 313 (1992-08-01), None
patent: 0 522 808 (1993-01-01), None
patent: 0 533 280 (1993-03-01), None
patent: 0 615 751 (1994-09-01), None
patent: 0 627 221 (1994-12-01), None
patent: 0 769 300 (1997-04-01), None
patent: 2 100 259 (1982-12-01), None
patent: 2 152 049 (1985-07-01), None
patent: 2 216 529 (1989-10-01), None
patent: 910819 (1991-09-01), None
patent: 913831 (1992-05-01), None
patent: 60-214784 (1985-10-01), None
patent: 62-252764 (1987-11-01), None
patent: 63-196583 (1988-08-01), None
patent: 3-503768 (1991-08-01), None
patent: WO 90/05729 (1990-05-01), None
patent: WO 91/02745 (1991-03-01), None
patent: WO 91/12266 (1991-08-01), None
patent: WO 91/18016 (1991-11-01), None
patent: WO 92/17449 (1992-10-01), None
patent: 93/00330 (1993-01-01), None
patent: WO 93/00331 (1993-01-01), None
patent: WO 93/01170 (1993-01-01), None
Niel,Arch. int. Physiol. Biochim. Biophys., 99, 5, A65-A76, 1991.
Leslie,Neurochem. Int., 7(2) 191-211, 1985.
Andrews et al.,TIPS, 9, 334-341, 1988.
Carpenter et al.,Cell and Mol. Neurobiol., 3(2) 113-126, 1983.
Carpenter et al.,Fed. Prod. Am. Sco. Exp. Biol., 43(15), 2952-2954, 1984.
Saffroy et al.,Peptides, 9, 227-241, 1988.
Tattersall et al.,European Journal of Pharmacology, 250, R5-R6, Nov. 1, 1993.
Henry et al. (editors), Substance P and Neurokinins—Springer Verlag 1987, p. XVII-XVIII.
Ekstrom et al., British Journal of Pharmacology, 94(3): 707-712 (1988).
Kambam et al., Anaesthesiology, 73(3A), Abstract A10 (1990).
Bountra et al.,European Journal of Pharmacology, 249, R3-R4, Nov. 1, 1993.
Current Medication Manual, Rev. Ed. Nihon Rinsho, Occasional Pub., pp. 482-483, 676 (1986).
Handbook of Medicaments, 4th Ed, Yakugyo-Jihoh K. K., pp. 1504-1505 (1989).
Martindale, 29th Ed. pp. 722-725 (1989).
Pharmacology, Hirokawa Pub. Co., p. 21. (Feb. 25, 1992).
Stedman's Medical Dictionary, 3rd Ed., Medical View Co Ltd, p. 112 (May 10, 1992).
Camu et al., European Journal of Anaesthesiology, 9 (Suppl. 6), pp. 25-31 (1992).
Lee et al., Naunyn-Schmiedebergs Arch Pharmacol, 318, pp. 281-287 (1982).
W.A. Marasco et al., Biochemical and Biophysical Research Communications, 99(4), pp. 1065-1072 (Apr. 30, 1981).
D. Regoli et al., Tachykinin Antagonists, (Hakanson & Sundler Eds) Elsevier Sci. Pub., Amsterdam, p. 277-287 (1985).
Takagi & Ozawa, Pharmacoglogy (Pocket Ed), Nanzando Co., Ltd. p. 18 (1987).
Ward et al., J. Med. Chem., 38, pp. 4985-4992 (1995).
Michael Wu et al., Peptides, 6, Suppl. 1, pp. 173-175 (1985).
Wynn et al., European Journal of Pharmacology, 241, pp. 47-54 (1993).
Proceedings of “Substance P and Neurokinins—Montreal 1986”, A Satellite Symposium of the XXX International Congress of the International Union of Physiological Sciences, J.L. Henry et al., Editors.
A.F. Ghouri et al., Anesthesiology, 73(3A) p. 9 (Sep. 1990).
Domenico Regoli et al., TIPS, 9, pp. 290-295 (Aug. 1988).
P.L.R. Andrews et al., TIPS, 9, pp. 334-341, (Sep. 1988).
Brown et al., Tachykinin Antagonists, Hakanson R. and Sundler, F. (Eds.) Elsevier:Amsterdam, pp. 305-312 (1985).
J.W. Dalley et al., Journal of Psychopharmacology, 4(4), p. 285, 1990 (Abstract).
David O. Carpenter et al., Final Report No. USAFSAM-TR-83-41, Peptide-Induced Emesis in Dogs, Oct. 1983.
T.D. Walsh et al., The Pharmaceutical Journal, pp. 525-527 (Oct. 29, 1983).
Vincent Gotz et al., on Continuing Practice, 8(4), pp. 11-20 (1981).
Shinya Ueno et al., Life Sciences, 41(4), pp. 513-518 (1987).
Shinya Ueno et al., Life Sciences, 43(5), pp. 413-420 (1988).
G. A. Saab, Am J Clin Oncol, 11(4), pp. 470-473 (1988).
Kathryn Louise Wood, Ph.D Thesis, Univ. London, 1988, paragraphs 2.5 and 2.7.
R.A. Leslie, Neurochem. Int., 7(2), pp. 191-211 (1985).
David O. Carpenter et al., Final Report No. USAFSAM-TR-82-28, USAF School of Aerospace Medicine, 1982, paragraph 2.8.
J.P. Miolan et al., Neuropeptides, 12, pp. 243-248 (1988).
V.V. Yasnetsov et al., Byulleten Eksperimentalnoi Biologii I Meditsiny, 103(5), pp. 586-588 (May 1987) (Translation).
V.S. Shashkov et al., Farmakologiia I Toksikologiia, 51(2), pp. 30-36, (Mar.-Apr. 1988) (Translation).
Yu. V. Drozd et al., Byulleten Eksperimentalnoi Biologii I Meditsiny, 106(7), pp. 50-52 (1988) (Translation).
V.V. Yasnetsov et al., Kosmicheskaia Biologii I Aviakosmicheskaia Meditsina, 22(2) pp. 72-73 (1988) (Translation).
R. Michael Snider et al., Science, Reports, pp. 435-437, (Jan. 25, 1991).
Patrick W. Mantyh, J. Clin. Psychiatry, 63, Suppl. 11, pp. 6-10, (2002).
Dan L. Longo et al., Cancer Treatment Reports, 66(11), pp. 1975-1976 (Nov. 1982).
Nicolas Tsavaris et al., Journal of Pain and Symptom Management, 6(8), pp. 461-465, Nov. 1991.
Merck Index, 11thEd, p. 1082 (1989).
New Compendium of Internal Medicine, 1, pp. 281-294 (1975).
New Compendium of Internal Medicine, 6, pp. 173-188 (1977).
Brain & Nerve, 20, pp. 959-963 (1968) (with English abstract).
Dam et al., Peptides, (7), pp. 855-864 (1986).
Butler, A., et al., Pharmacological Properties of GR 38032F, a novel antagonist at 5-HT3receptors, British Journal of Pharmacology, 94(2), pp. 397-412 (1988).
Bradley et al., “Proposal for the Classification and Nomenclature of Functional Receptors for 5-hydroxytryptamine,” Neuropharmacology, 25(6), pp. 563-576 (1986).
Ctr. for Drug Evaluation and Research, Food and Drug Admin.,Electronic Orange Book(24thed. Cum. Supp. Jun. 6, 2004) at http://www.fda.gov/cder/ob/, query “Alosetron”. Patent data last updated Aug. 11, 2004.
Physicians' Desk Reference, PDR® Eelctronic Library™, PDR Entry for EMEMD® (Aprepitant), printed from website on Aug. 11, 2004.
Ctr. for Drug Evaluation and Research, Food and Drug Admin.,Electronic Orange Book(24thed. Cum. Supp. Jun. 6, 2004) at http://www.fda.gov/cder/ob/, query “Aprepitant”. Patent data last updated Aug. 5, 2004.
Physicians' Desk Reference, PDR® Eelctronic Library™, PDR Entry for ANZEMET® (Dolasetron), printed from website on Au

Affiliated with

Also associated with

Rating

Medical use for tachykinin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical use for tachykinin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical use for tachykinin antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811361